Jul 30 |
Roche’s Vabysmo challenges Eylea dominance with third European indication
|
Jul 30 |
BioNTech posts mid-stage win for mRNA cancer drug with Regeneron’s Libtayo
|
Jul 30 |
The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Regeneron and Optex Systems
|
Jul 29 |
Top Analyst Reports for Goldman Sachs, RTX & Regeneron
|
Jul 29 |
Countdown to Regeneron (REGN) Q2 Earnings: Wall Street Forecasts for Key Metrics
|
Jul 29 |
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
|
Jul 27 |
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
|
Jul 26 |
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
|
Jul 25 |
Regeneron (REGN) Earnings Expected to Grow: Should You Buy?
|
Jul 25 |
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
|